• Something wrong with this record ?

The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma

V. Scudla, T. Pika, M. Budikova, J. Petrova, J. Minarik, J. Bacovsky, K. Langova, J. Zivna

. 2010 ; 57 (2) : 102-110.

Language English Country Slovakia

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
NR9489 MZ0 CEP Register
NR9500 MZ0 CEP Register

The study aimed at evaluating the relation of 7 parameters associated with the internal biological properties of myeloma cells and the bone marrow microenvironment to multiple myeloma (MM) stages, distinguishing its initial/asymptomatic phase from monoclonal gammopathy of undetermined significance (MGUS) and assessing their relation to myeloma prognosis. In the studied group comprising 286 individuals (89 MGUS and 179 MM patients), statistically significant differences (Mann-Whitney test) between MGUS and MM at the time of diagnosis were found in the serum levels of HGF (hepatocyte growth factor), VEGF (vascular endothelial growth factor), ICTP (intercellular - carboxy-terminal telopeptide of type I collagen), PINP (procollagen type I N-terminal propeptide), OPG (osteoprotegerin) and syndecan-1/CD138, but not in Fas. Multivariate analysis (logistic regression) revealed an unsatisfactory potential of all the 7 studied indicators to discriminate between MGUS and MM. A deeper analysis showed statistically significant differences between MGUS and the initial/asymptomatic phase of MM (stage 1 according to the International Staging System) only in the cases of syndecan-1 (p=0.001) and Fas (p=0.008). The assessment of initial values of HGF, VEGF, ICTP, PINP, OPG, syndecan-1 and Fas showed a statistically significant relation (log rank test) to the overall survival (OS) in a group of 132 patients treated with conventional chemotherapy only in the cases of syndecan-1 (p=0.0002) and Fas (p=0.018), but in none of the investigated parameters in a group of 74 patients treated with HDT/ASCT (high-dose therapy/autologous stem cell transplantation). The analysis showed that, despite significant differences in serum levels of 6 of the 7 studied parameters found between MGUS and MM, none of the markers may be included in the spectrum of indicators used to distinguish the two conditions. Despite the positive relation, especially of syndecan-1 and, to a lesser extent, of Fas to the OS in patients treated with conventional chemotherapy, these prognostic factors are not applicable to HDT/ASCT.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12025271
003      
CZ-PrNML
005      
20140724112908.0
007      
ta
008      
120816s2010 xo f 000 0#eng||
009      
AR
024    7_
$a 10.4149/neo_2010_02_102 $2 doi
035    __
$a (PubMed)20099972
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Ščudla, Vlastimil, $d 1946- $7 jn20000402953 $u Department of Internal Medicine III, University Hospital, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. vlastimil.scudla@fnol.cz
245    14
$a The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma / $c V. Scudla, T. Pika, M. Budikova, J. Petrova, J. Minarik, J. Bacovsky, K. Langova, J. Zivna
520    9_
$a The study aimed at evaluating the relation of 7 parameters associated with the internal biological properties of myeloma cells and the bone marrow microenvironment to multiple myeloma (MM) stages, distinguishing its initial/asymptomatic phase from monoclonal gammopathy of undetermined significance (MGUS) and assessing their relation to myeloma prognosis. In the studied group comprising 286 individuals (89 MGUS and 179 MM patients), statistically significant differences (Mann-Whitney test) between MGUS and MM at the time of diagnosis were found in the serum levels of HGF (hepatocyte growth factor), VEGF (vascular endothelial growth factor), ICTP (intercellular - carboxy-terminal telopeptide of type I collagen), PINP (procollagen type I N-terminal propeptide), OPG (osteoprotegerin) and syndecan-1/CD138, but not in Fas. Multivariate analysis (logistic regression) revealed an unsatisfactory potential of all the 7 studied indicators to discriminate between MGUS and MM. A deeper analysis showed statistically significant differences between MGUS and the initial/asymptomatic phase of MM (stage 1 according to the International Staging System) only in the cases of syndecan-1 (p=0.001) and Fas (p=0.008). The assessment of initial values of HGF, VEGF, ICTP, PINP, OPG, syndecan-1 and Fas showed a statistically significant relation (log rank test) to the overall survival (OS) in a group of 132 patients treated with conventional chemotherapy only in the cases of syndecan-1 (p=0.0002) and Fas (p=0.018), but in none of the investigated parameters in a group of 74 patients treated with HDT/ASCT (high-dose therapy/autologous stem cell transplantation). The analysis showed that, despite significant differences in serum levels of 6 of the 7 studied parameters found between MGUS and MM, none of the markers may be included in the spectrum of indicators used to distinguish the two conditions. Despite the positive relation, especially of syndecan-1 and, to a lesser extent, of Fas to the OS in patients treated with conventional chemotherapy, these prognostic factors are not applicable to HDT/ASCT.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a kolagen typu I $7 D024042
650    _2
$a diferenciální diagnóza $7 D003937
650    _2
$a ELISA $7 D004797
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hepatocytární růstový faktor $x krev $7 D017228
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a monoklonální gamapatie nejasného významu $x krev $x diagnóza $7 D008998
650    _2
$a mnohočetný myelom $x krev $x diagnóza $7 D009101
650    _2
$a staging nádorů $7 D009367
650    _2
$a osteoprotegerin $x krev $7 D053244
650    _2
$a peptidové fragmenty $x krev $7 D010446
650    _2
$a peptidy $7 D010455
650    _2
$a prokolagen $x krev $7 D011347
650    _2
$a prognóza $7 D011379
650    _2
$a syndekan-1 $x krev $7 D053668
650    _2
$a nádorové biomarkery $x krev $7 D014408
650    _2
$a vaskulární endoteliální růstový faktor A $x krev $7 D042461
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pika, Tomáš $7 xx0071238 $u Department of Internal Medicine III, University Hospital, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Budíková, Marie $7 xx0172938 $u Department of Clinical Biochemistry, University Hospital, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Petrová, J $u Department of Clinical Biochemistry, University Hospital, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Minařík, Jiří $7 xx0106330 $u Department of Internal Medicine III, University Hospital, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Bačovský, Jaroslav $7 xx0053311 $u Department of Internal Medicine III, University Hospital, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Langová, Kateřina $7 xx0141371 $u Department of Medical Biophysics, University Hospital, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1#
$a Živná, Jarmila, $d 1953- $7 xx0208844 $u Department of Haematology, Hranice Hospital, Czech Republic
773    0_
$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 57, č. 2 (2010), s. 102-110
856    41
$u https://pubmed.ncbi.nlm.nih.gov/20099972 $y Pubmed
910    __
$a ABA008 $b A 1194 $c 659 $y m $z 0
990    __
$a 20120816 $b ABA008
991    __
$a 20140724113219 $b ABA008
999    __
$a ok $b bmc $g 947313 $s 782617
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 57 $c 2 $d 102-110 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
GRA    __
$a NR9489 $p MZ0
GRA    __
$a NR9500 $p MZ0
LZP    __
$a Pubmed-20120816/10/02

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...